Citations

Clear

2249 citation(s) found for "Gök, Ali".

Clinical phenotypes, autoimmunity and outcomes in Rosai–Dorfman disease: An international multicentre cohort study
Sen, Mitali , Ruan, Gordon J , Reynolds, Samuel , Ali, Haadi , Morlote, Diana M. , Koster, Matthew J , Abeykoon, Jithma P , Salama, Hind , Ahmed, Asra Z , Go, Ronald S , Goyal, Guarav

Mayo Clinic

British Journal of Haematology | November 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/bjh.70939 | PMID 43014348 Get It

Summary Rosai–Dorfman disease (RDD) is a rare histiocytic neoplasm with diverse clinical behaviour and immune abnormalities with unknown clinical significance. We performed a retrospective cohort study of 162 patients with RDD from 2003 to 2025 at five international referral centres. Median age was 48 years and 64.8% were female. Multisystem disease occurred in 87 patients (53.7%), commonly involving skin/subcutaneous tissue (49.4%), lymph nodes (39.5%) and bones (34%). Molecular testing was available for 102 patients; 40 (39.2%) were mitogen‐activated protein kinase/rat sarcoma virus oncogene homolog signaling pathway (MAPK/RAS)‐altered, commonly with kirsten rat sarcoma viral oncogene homolog ( KRAS ) or mitogen‐activated protein kinase 1 ( MAP2K/MEK ) alterations. MAPK/RAS alterations were associated with multisystem disease ( p = 0.0034). Autoimmune disease (AID) was documented in 29 patients (17.9%), usually preceding RDD, and 45/95 patients (47.4%) with available autoantibody status had at least one positive autoantibody. Among 153 patients with response data, objective response occurred in 94 (61.4%). Response distribution differed by disease extent; single‐system disease was associated with more complete responses and less progression than multisystem disease. At a median follow‐up of 2.49 years, eight deaths occurred; 5‐year overall survival was 93.4%. AID and autoantibody positivity were not associated with response or overall survival. These findings support disease extent and molecular status as clinically relevant dimensions of RDD assessment, while autoimmune and serological abnormalities should be interpreted in clinical context.
Evaluating Age-Related Motor System Changes Using Gait as a Functionally Relevant Marker
You, Victor S , Barnard, Leland , Botha, Hugo , Graff-Radford, Jonathan , Vemuri, Prashanthi , Jack, Clifford R , Knopman, David S. , Windham, Beverly Gwen , Petersen, Ronald C , Ali, Farwa

Mayo Clinic

Neurology | November 10, 2026 | Volume: 107 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000218766 | PMID 43008257 Get It

Complications and Hospital Resource Utilization Associated with ECMO in COVID-19 ARDS with Acute Kidney Injury: Insights from United States National Inpatient Sample, 2020–2022
Arumairaj, Antony , Dhorajiya, Poojaben , Dhanani, Dili , Venkataswamy Reddy, Jyothika , Kumar, Abhishek Kumar Mariswamy Arun , Tashrifwala, Fatema Ali Asgar , Patel, Digantkumar , Korpu, Divya , Mittal, Jayesh

Mayo Clinic

Healthcare | October 19, 2026 | Volume: 14 | Issue: 20 | Pages: 3490

10.3390/healthcare14203490 | PMID 42940536 Get It

Background: Acute kidney injury (AKI) is a common complication of COVID-19-associated acute respiratory distress syndrome (ARDS), yet the impact of extracorporeal membrane oxygenation (ECMO) on outcomes in this high-risk population remains unclear. Methods: We performed a retrospective, survey-weighted study using the National Inpatient Sample (NIS) database from 2020–2022 to compare outcomes among adults hospitalized with COVID-19-associated ARDS and AKI managed with invasive mechanical ventilation (IMV) alone versus IMV and ECMO. The primary outcome was in-hospital mortality, while secondary outcomes included renal replacement therapy (RRT), complications, hospital length of stay (LOS), and healthcare utilization. Results: Among 198,395 hospitalizations with COVID-19 ARDS complicated by AKI, 4730 received IMV and ECMO. ECMO use was not associated with statistically significantly lower adjusted in-hospital mortality (adjusted odds ratio [aOR] 0.96, 95% CI 0.81–1.12). However, ECMO was associated with greater odds of RRT, intracranial hemorrhage, disseminated intravascular coagulation, cardiogenic shock, vasopressor use, tracheostomy, acute liver failure, deep vein thrombosis, ischemic stroke and ICU-acquired weakness. ECMO was also associated with longer LOS and higher hospitalization charges. Conclusions: Among hospitalizations with COVID-19-associated ARDS and AKI, ECMO was not associated with statistically significantly lower adjusted in-hospital mortality but was associated with markedly higher complication burden, longer hospitalization, and substantially greater healthcare resource utilization.
The hearing healthcare workforce: insights into density, distribution and opportunities for capacity-development
Mokoh, Lilian , Law, Shen Hong , Jaffer, Ali F. , Seguya, Amina , Kahinga, Aveline Aloyce , Nakku, Doreen , Holt, Elizabeth A.L. , Dillard, Lauren K. , Zalaquett, Nader , Frost, Robert, Patterson, Rolvix H. , Nuss, Sarah , Xu, Mary Jue , Elwell, Zachary , Waterworth, Christopher J.

Mayo Clinic

International Journal of Audiology | October 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-13

10.1080/14992027.2026.2738096 | PMID 42860054 Get It

Combined Effect of Obstructive Sleep Apnea and Preserved Ratio Impaired Spirometry on Cardiovascular Outcomes
Chen, Lida , Dong, Yunzhou , Karim, Shahid , Wang, Jingjing , Ali, Isra H , Somers, Virend K.

Mayo Clinic

Journal of the American Heart Association | October 10, 2026 | Volume: 15 | Issue: 20 | Pages: No page available

10.1161/jaha.126.052921 | PMID 42857998 Get It

Background Obstructive sleep apnea (OSA)–chronic obstructive pulmonary disease overlap syndrome has been linked to worse cardiovascular outcomes. Preserved ratio impaired spirometry (PRISm) is recognized as an early stage of chronic obstructive pulmonary diseas. However, whether the coexistence of OSA and PRISm confers increased cardiovascular risk remains unknown. Methods Using data from the Sleep Heart Health Study, participants were categorized into 4 groups according to OSA and PRISm status. The primary outcome was major adverse cardiovascular and cerebrovascular events. The secondary outcome was cardiovascular disease mortality. Multivariable Cox regression models were used to evaluate the association of these groups with the risk of cardiovascular outcomes. Results During a median follow‐up of 11.45 years, the incidence of major adverse cardiovascular and cerebrovascular events was 17.00% in non‐OSA with normal lung function, 27.52% in non‐OSA with PRISm, 25.28% in OSA with normal lung function, and 49.40% in OSA with PRISm. After multivariable adjustment, compared with non‐OSA with normal lung function, the adjusted hazard ratios (HRs) for major adverse cardiovascular and cerebrovascular events were 1.20 (95% CI, 0.82–1.75) in non‐OSA with PRISm, 1.04 (95% CI, 0.89–1.21) in OSA with normal lung function, and 1.52 (95% CI, 1.08–2.12) in OSA with PRISm. Corresponding HRs for CVD mortality were 2.02 (95% CI, 1.26–3.24), 1.05 (95% CI, 0.81–1.35), and 2.17 (95% CI, 1.41–3.34), respectively. A significant sex interaction was observed ( P for interaction=0.009), with the association present only in women. Conclusions The coexistence of OSA and PRISm is independently associated with increased risk of adverse cardiovascular outcomes. This association is observed predominantly in women.
Metabolic reprogramming of pathogenic CD4 + T helper cells attenuates inflammatory bowel disease in mice
Mishra, Shravan K , Abdelrahman, Leena M , Kim Lee, Hyun Se , Valenzuela-Pérez, Lucía , Manna, Dina Faeq , Abram, Tanner J , Ali, Lama Mohamed , Davidson, Heidi M , Hassan, Omar M , Faubion, William A. , Hirsova, Petra , Bamidele, Adebowale O

Mayo Clinic

Science Signaling | October 6, 2026 | Volume: 19 | Issue: 958 | Pages: No page available

10.1126/scisignal.aeb2392 | PMID 42837442 Get It

CD4 + effector T helper 1 (T H 1) cells drive inflammatory bowel disease (IBD). Here, we investigated how integrated signaling, metabolic, and epigenetic programs sustain their pathogenic persistence. We found that enforcing mitochondrial pyruvate metabolism with methyl pyruvate (MePyr) suppressed T H 1 cell effector function and induced the acquisition of a regulatory-like phenotype. MePyr suppressed the activity of glycogen synthase kinase 3β (GSK3β), promoting a metabolic shift from glycolysis toward oxidative phosphorylation (OXPHOS) and limiting the accumulation of intracellular acetyl-CoA. This metabolic reprogramming decreased histone H3 acetylation at genes encoding inflammatory cytokines, thereby decreasing T H 1 cell–associated gene expression. Restoration of inflammatory cytokine production by acetate supplementation or histone deacetylase inhibition established acetyl-CoA–dependent histone acetylation as a mechanistic link between metabolic flux and effector function. Conversely, the cytokine interleukin-21 enhanced T H 1 cell effector activity by promoting a GSK3β-dependent shift from OXPHOS to glycolysis. Single-cell transcriptomic analysis of Crohn’s disease tissue revealed enrichment of glycolytic gene programs in nonregulatory CD4 + T cells. Consistent with these findings, pharmacologic inhibition of GSK3β attenuated disease severity in a T cell–transfer mouse model of colitis. Together, these findings identify a GSK3β-dependent metabolic-epigenetic axis that sustains T H 1 cell pathogenicity and highlight GSK3β as a potential therapeutic target for IBD.
Rheumatoid Arthritis, Frailty, and Outcomes of Surgical Hospitalizations: A National Population‐Based Analysis
Yazdanyar, Ali , Baker, Joshua F. , Wysham, Katherine D. , Yousufuddin, Mohammed , Kaiksow, Farah Acher , Ward, Michael M.

Mayo Clinic

Arthritis Care & Research | September 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/acr.80171 | PMID 42806885 Get It

Objective Hospitalization, particularly for surgery, represents a period of heightened stress. We evaluated how frailty attenuates the association of rheumatoid arthritis (RA) with negative health outcomes after elective noncardiac surgery. Methods We conducted a cross‐sectional study using the National Inpatient Sample (2018 to 2020), including adults (aged ≥18 years) with elective hospitalizations with noncardiac surgery. Frailty was measured using the Hospital Frailty Risk Score (HFRS). Surgeries were categorized by risk level. Outcomes included discharge health resources need (DHRN), composite adverse clinical events (CACE), and death. Results Among 8,800,359 hospitalizations (2.14% among patients with RA), 73.36% underwent intermediate‐risk surgery and 62.25% had HFRS above 0. DHRN occurred in 28.9%, CACE occurred in 0.93%, and all‐cause mortality occurred in 0.17%. A 10‐point increase in HFRS was associated with a 3.8‐fold increased DHRN, 8.5‐fold increased CACE, and 22.8‐fold increased mortality. RA was not independently associated with CACE (adjusted odds ratio [aOR] 0.91; 95% confidence interval [CI] 0.82–1.01; P = 0.08) or death (aOR 0.90; 95% CI 0.71–1.15; P = 0.41) but was significantly associated with DHRN (aOR 1.28, 95% CI 1.25–1.31; P < 0.001) after adjusting for confounders and frailty. In sensitivity analysis, RA had 10% higher relative odds of DHRN following orthopedic (aOR 1.10; 95% CI 1.07–1.13; P < 0.001) but not nonorthopedic intermediate‐risk surgery (aOR 1.10; 95% CI 0.98–1.23; P = 0.11). Conclusion RA was associated with higher odds of DHRN after orthopedic intermediate‐risk surgery but not CACE or inpatient mortality. Moreover, HFRS was associated with DHRN, CACE, and death. These findings underscore the need for disease‐specific clinical considerations and highlight the potential utility of HFRS in discharge planning.
Hormone Replacement Therapy and Recurrence Risk in Postmenopausal Idiopathic Subglottic Stenosis
Awadallah, Andrew S. , Fearington, Forrest W. , Ali, Hawa M., Li, Yan, Rutt, Amy L. , Edell, Eric S. , Koster, Matthew J. , Bayan, Semirra L. , Ekbom, Dale C. , Awadallah, Andrew

Mayo Clinic

Otolaryngology–Head and Neck Surgery | September 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ohn.70448 | PMID 42782084 Get It

Abstract Objective To evaluate whether systemic hormone replacement therapy (HRT) influences recurrence outcomes in postmenopausal patients with idiopathic subglottic stenosis (iSGS). Study Design Retrospective cohort study. Setting Tertiary academic medical center. Methods Postmenopausal women (≥50 years) with iSGS who underwent laser‐wedge excision between 2002 and 2024 were included. Patients were categorized by systemic HRT exposure (oral estrogen, progesterone, combined estrogen‐progesterone, or transdermal estrogen) at or before their first surgery. Overdispersion was assessed for all Poisson models; given significant overdispersion, negative binomial regression with a log‐offset for follow‐up time was used as the primary model. Surgery‐free intervals were analyzed using linear mixed models, and time to first recurrence using Cox regression. Models were adjusted for age, body mass index (BMI), parity, oophorectomy, follow‐up length, surgery type, and serial intralesional steroid injections (SILSI) use. Results Among 125 patients, 96 had never used HRT (Never HRT) and 29 used HRT, including 19 actively using HRT at presentation (Current HRT), 5 past users, and 5 subsequent users. The HRT versus Never‐HRT recurrence rate comparison was not significant (adjusted incidence rate ratio [IRR] = 0.81, 95% CI: 0.48‐1.37, P = .422). However, Current HRT use was associated with a 53% lower adjusted recurrence rate versus Never‐HRT use (adjusted IRR = 0.47, 95% CI: 0.25, 0.89, P = .0203). Surgery‐free intervals and time to first recurrence trended longer in Current HRT users but were not statistically significant. Conclusion Current HRT use at presentation was associated with significantly fewer recurrences in postmenopausal iSGS patients. These findings may inform individualized, shared decision‐making regarding HRT use in this population. Level of Evidence 3.
Graph-Enhanced Retrieval-Augmented Generation for Postoperative Patient Question Answering: A Comparative Evaluation of Knowledge Graph, Retrieval-Augmented Generation, and Hybrid GraphRAG Approaches
Prabha, Srinivasagam, Collaço, Bernardo Gabriele , Rosa Malena, Carina , Haider, Syed Ali , Wood, Nadia , Forte, Antonio J. , Forte, Antonio Jorge , Haider, Syed A , Wood, Nadia , Collaco, Bernardo G , Prabha, Srinivasagam

Mayo Clinic

Bioengineering | September 22, 2026 | Volume: 13 | Issue: 10 | Pages: 1097

10.3390/bioengineering13101097 | PMID 42938952 Get It

Background: Reliable access to postoperative guidance between clinic visits remains inconsistent, and the usefulness of large language models depends on how clinical knowledge is structured and retrieved. Knowledge graph-only (KG-only), vector retrieval-augmented generation (RAG-only), and hybrid graph-retrieval (GraphRAG) architectures have not been directly compared under controlled conditions for postoperative care. Objective: It was to compare these three pipelines on a curated postoperative question-answering benchmark using automated grounding metrics and blinded clinician review. Methods: A benchmark of 250 expert-authored questions (200 in-scope, 20 emergency-intent, 30 out-of-scope) was evaluated on an identical knowledge corpus using Gemini 2.5 Flash for generation and Gemini Embedding-001 for retrieval. Three blinded clinicians rated all 750 outputs; the primary outcome was majority-consensus accuracy across all 250 questions. GraphRAG is a multi-component pipeline that also includes query expansion, a second retrieval stage, evidence fusion, and a monotonic RAG fallback, and is therefore evaluated as a complete hybrid system rather than as graph retrieval in isolation. Results: Overall accuracy was 96.8% (95% CI: 93.8–98.4) for GraphRAG, 94.8% (95% CI: 91.3–96.9) for RAG-only, and 56.0% (95% CI: 49.8–62.0) for KG-only. Both retrieval-augmented systems outperformed KG-only (adjusted p < 0.001). The GraphRAG versus RAG-only difference was 2.0 percentage points, arose from five discordant question pairs and did not reach the Bonferroni-adjusted threshold (exact McNemar p = 0.062; adjusted p = 0.188). The monotonic RAG fallback determined 44.8% of GraphRAG outputs (112 of 250 queries). GraphRAG showed higher context recall (0.851 versus 0.796; adjusted p < 0.001), whereas RAG-only showed higher context precision. Estimated hallucination risk, derived from an LLM-as-a-judge procedure using Gemini 2.5 Flash rather than independent clinical adjudication, was 0.108, 0.132, and 0.436, respectively; the GraphRAG versus RAG-only difference was not significant (adjusted p = 0.771). Inter-rater agreement was high (Fleiss’ kappa = 0.854). Conclusions: Retrieval augmentation, rather than the choice of retrieval architecture, accounted for most of the difference observed. The incremental advantage of GraphRAG over a well-implemented RAG-only system was small, was not statistically significant after correction and reflects the complete hybrid system rather than graph augmentation alone. Emergency-intent accuracy was 75.0% for both retrieval-augmented systems; the architecture is therefore suited to supervised clinical workflows with clinician review, not autonomous patient-facing triage. Prospective validation on authentic patient messages and formal component ablations are required.
Toxicity Attribution During Enfortumab Vedotin Plus Pembrolizumab Therapy in Urothelial Carcinoma: A Practical Framework
Zarka, Jabra, Childs, Daniel S. , Rincón, Miguel Muñiz, Tarhini, Ali , Jang, Albert , Kottschade, Lisa A. , Markovic, Svetomir N, Spychalla, Megan, Sitenga, Morgan, NGUYEN, GIANG, Pagliaro, Lance, Costello, Brian A, Orme, Jacob J., Zarka, Jabra G , Muniz Rincon, Miguel, Tarhini, Ali , Muniz, Miguel , Jang, Albert , Zarka, Jabra , Jang, Albert , Spychalla, Megan, Pagliaro, Lance C. , Costello, Brian A. , Orme, Jacob J.

Mayo Clinic

The Oncologist | September 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/oncolo/oyag371 | PMID 42768457 Get It

Abstract Enfortumab vedotin (EV), pembrolizumab, and EV plus pembrolizumab (EV/P) have rapidly reshaped the treatment landscape of advanced urothelial carcinoma, but toxicity increasingly determines treatment delivery, treatment continuity, and real-world benefit. As EV/P moves into broader clinical use, clinicians must distinguish adverse events related to antibody-drug conjugate exposure from immune-mediated toxicities and recognize syndromes in which both mechanisms may contribute. In this practical, mechanism-informed review, we synthesize pivotal trials, mature follow-up reports, and representative real-world cohorts describing the safety of EV monotherapy, pembrolizumab monotherapy, and EV/P in urothelial carcinoma. Because adverse-event reporting and ascertainment are heterogeneous across studies, including differences in preferred terms, composite categories, grading frameworks, and treatment-related versus all-cause reporting, we emphasize clinically interpretable patterns rather than pooled estimates. EV monotherapy is characterized by cutaneous toxicity, peripheral neuropathy, hyperglycemia, dysgeusia, and ocular events, including early epithelial/metabolic events and cumulative neuropathy. Pembrolizumab monotherapy has a lower overall high-grade toxicity burden but is defined by immune-mediated endocrinopathies, pneumonitis, hepatitis, colitis, and nephritis. Combination therapy produces a predictable overlap of these toxicity domains, creating diagnostic and management challenges for syndromes such as skin toxicity, diarrhea, fatigue, and pulmonary symptoms. We provide comparative visual toxicity signatures, regimen-specific summary tables, temporal toxicity mapping, and a pragmatic attribution framework that classifies events as EV-predominant, immune-predominant, overlap/indeterminate, or high-risk requiring initial interruption of both agents. This review aims to support bedside recognition, provisional attribution, early management, and safer implementation of EV/P in contemporary urothelial carcinoma practice.